LAS VEGAS, April 29, 2024 /PRNewswire/ -- DelveInsight's
Malignant Ascites Market Insights report includes a comprehensive understanding of current treatment practices, malignant ascites emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. USD 1.9 billion in 2020 across the 7MM, which is anticipated to rise to
Leading malignant ascites companies such as
The promising malignant ascites therapies in the pipeline include
Even with the new therapies coming in the market, still the mainstay treatment for Malignant Ascites will remain chemotherapy over the years. Out of the novel treatments, the highest revenue is expected to be generated by CATUMAXOMAB with 10.54% of share of the total market in 2034, followed by OK-432 with 2.21% of market share, respectively. Discover which therapies are expected to grab the major malignant ascites market share @ Malignant Ascites Market Report
Malignant Ascites Overview
Malignant ascites is a pathological condition stemming from various primary abdominal and non-abdominal cancers. It stands as a significant source of illness, presenting numerous complexities and treatment obstacles. It serves as an indicator of peritoneal carcinomatosis, denoting the presence of cancerous cells within the peritoneal cavity. Carcinomatosis-causing tumors are frequently secondary malignancies affecting the peritoneal surface, such as those from ovarian, colorectal, pancreatic, and uterine origins; as well as extraperitoneal tumors originating from lymphoma, lung, and breast cancers, alongside smaller proportion of unidentified primary tumors. Malignant Ascites Epidemiology Segmentation
The malignant ascites epidemiology section provides insights into the historical and current malignant ascites patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The malignant ascites market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Incident Cases of Ascites in Selected Indications (Ovarian, Colorectal, Gastric, and Others) Malignant Ascites Treatment Market
The available treatments for malignant ascites consist of various strategies designed to ease symptoms and enhance quality of life. These methods include draining fluids through paracentesis, using chemotherapy to combat cancer cells and lessen ascite formation, employing targeted therapy tailored to particular cancer types, opting for surgical procedures like tumor removal or shunt insertion, and incorporating supportive measures such as diuretics and nutritional assistance. The selection of treatment is determined by factors such as the specific cancer type and the severity of symptoms, with the main objective being the management of symptoms and the improvement of overall well-being. Malignant ascite treatments aimed at causing a reduction in malignant ascites mainly consist of systemic chemotherapy, targeted therapy, or surgical procedures designed to decrease or remove the cancerous tumors accountable for the development of ascites. These methods focus on the fundamental cause of ascites by dealing with the underlying cancer, intending to slow down the advancement of the disease and enhance the outcomes for the patient. With just two accepted treatments,
OK-432 and KM-CART, available in Japan, many patients are left with only palliative care, which often falls short of addressing their needs. Various methods exist to relieve symptoms linked with malignant ascites. However, due to a lack of understanding of ascites' natural progression, there is limited data on these approaches and their impact on quality of life. Assessing the effectiveness of current treatments is challenging. Common traditional methods for handling malignant ascites encompass sodium-restricted diets, diuretic treatment, repeated paracentesis, and peritoneovenous shunting. Malignant Ascites Management
Malignant Ascites Pipeline Therapies and Key Companies
M 701: WUHAN YZY BIOPHARMA CO., LTD.
VAK: BINHUI BIOPHARMACEUTICAL
Malignant Ascites Market Dynamics
The dynamics of the malignant ascites market are expected to change in the coming years. SCB-313 utilizes distinctive, patented protein trimerization technology to precisely target and activate the triple-dependent mechanism of tumor cell apoptosis, fostering collaboration among oncologists, surgeons, researchers, and other healthcare professionals to develop effective management strategies, identification of novel therapeutic targets through advanced molecular analyses, and an emphasis on patient-centered care and improved symptom management to enhance the overall
Furthermore, many potential therapies are being investigated for the treatment of malignant ascites, and it is safe to predict that the treatment space will significantly impact the malignant ascites market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further
improvement in the diagnosis rate are expected to drive the growth of the malignant ascites market in the 7MM.
However several factors may impede the growth of the malignant ascites market. Tackling malignant ascites poses ongoing difficulties in clinical management, with the current focus primarily on alleviating symptoms rather than achieving a definitive cure, due to the
absence of universally accepted treatment protocols stemming from
limited evidence and patient heterogeneity; consequently, malignant ascites also presents research obstacles, with only a few attempts made to develop medications for the condition, and the potential hindrance of access to emerging therapies once approved by the availability of off-label therapies.
Moreover, malignant ascites treatment poses a
significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the malignant ascites market growth may be offset by
failures and discontinuation of emerging therapies,
market access and reimbursement issues, and a
shortage of healthcare specialists. In addition, the
undiagnosed, unreported cases and the unawareness about the disease may also impact the malignant ascites market growth.
Therapeutic Assessment: Malignant Ascites current marketed and emerging therapies
Market Dynamics: Key Market Forecast Assumptions of Emerging Malignant Ascites Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Malignant Ascites Market Access and Reimbursement Malignant Ascites Clinical Trials
Malignant Ascites Pipeline
Malignant Ascites Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant ascites companies, including Malignant Ascites Epidemiology Forecast
Malignant Ascites Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted malignant ascites epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Ascites Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ascites companies, including
Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, among others. Ascites Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ascites companies, including
Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, among others. DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg